Zuclopenthixol decanoate maintenance dosing after initial period?

Zuclopenthixol decanoate maintenance dosing after initial period?

• A. 60 mg IM q4 weeks
• B. 20 mg/day PO
• C. 5 mg/day PO
• D. After 1st 8 weeks: 10 mg/day PO = 150 mg IM q2 weeks or 300 mg q4 weeks

Answer: (D)

Maintenance dosing for a long-acting injectable antipsychotic focuses on keeping drug levels steady after the initial stabilization period to prevent relapse and support adherence. For zuclopenthixol decanoate, once the patient has stabilized over the first couple of months, the recommended plan is to continue with depot injections on a fixed schedule that maintains similar monthly exposure as an oral dose, rather than daily pills. A common maintenance approach is 150 mg given IM every 2 weeks, or 300 mg IM every 4 weeks. These regimens provide consistent therapeutic levels and align with an oral equivalent of about 10 mg per day if an oral route is used. The idea is to choose a regimen that preserves steady-state levels and minimizes fluctuations, which helps prevent symptom recurrence. The alternatives—a monthly 60 mg injection, or daily oral doses of 20 mg or 5 mg—do not provide the same stable exposure or the practical, adherence-friendly schedule that depot therapy offers.

Maintenance dosing for a long-acting injectable antipsychotic focuses on keeping drug levels steady after the initial stabilization period to prevent relapse and support adherence. For zuclopenthixol decanoate, once the patient has stabilized over the first couple of months, the recommended plan is to continue with depot injections on a fixed schedule that maintains similar monthly exposure as an oral dose, rather than daily pills. A common maintenance approach is 150 mg given IM every 2 weeks, or 300 mg IM every 4 weeks. These regimens provide consistent therapeutic levels and align with an oral equivalent of about 10 mg per day if an oral route is used. The idea is to choose a regimen that preserves steady-state levels and minimizes fluctuations, which helps prevent symptom recurrence. The alternatives—a monthly 60 mg injection, or daily oral doses of 20 mg or 5 mg—do not provide the same stable exposure or the practical, adherence-friendly schedule that depot therapy offers.